Literature DB >> 30901127

Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Sukhpreet Klaire1, Rebecca Zivanovic2,3, Skye Pamela Barbic2,4,5, Raman Sandhu3, Nickie Mathew3,6, Pouya Azar2,3,7.   

Abstract

BACKGROUND AND OBJECTIVES: Buprenorphine/naloxone has been shown to be effective in the treatment of opioid use disorder. Due to its pharmacological properties, induction can be challenging, time-consuming, and result in sudden onset of withdrawal symptoms.
METHODS: Retrospective case series (n = 2).
RESULTS: Two patients with opioid use disorder were successfully started on buprenorphine/naloxone using a rapid micro-induction technique that did not cause precipitated withdrawal or require preceding cessation of other opioids. DISCUSSION AND
CONCLUSIONS: These cases provide an alternative method for starting buprenorphine/naloxone that offers unique benefits compared to protocols previously described in the literature. SCIENTIFIC SIGNIFICANCE: This method can be used to minimize barriers to opioid agonist therapy. (Am J Addict 2019;28:262-265).
© 2019 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30901127     DOI: 10.1111/ajad.12869

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  24 in total

1. 

Authors:  Radhika Marwah; Caitlin Coons; Jacqueline Myers; Zack Dumont
Journal:  Can Fam Physician       Date:  2020-12       Impact factor: 3.275

2.  Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.

Authors:  Sarah A Weicker; Kanna Hayashi; Cameron Grant; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2019-10-25       Impact factor: 4.492

3.  Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.

Authors:  Privia A Randhawa; Rupinder Brar; Seonaid Nolan
Journal:  CMAJ       Date:  2020-01-20       Impact factor: 8.262

Review 4.  Treating Chronic Pain with Buprenorphine-The Practical Guide.

Authors:  Amy A Case; Justin Kullgren; Sidra Anwar; Sandra Pedraza; Mellar P Davis
Journal:  Curr Treat Options Oncol       Date:  2021-11-18

5.  Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing - a case series.

Authors:  Rupinder Brar; Nadia Fairbairn; Christy Sutherland; Seonaid Nolan
Journal:  Drug Alcohol Rev       Date:  2020-07

6.  Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients.

Authors:  Victor M Tang; Jessica Lam-Shang-Leen; Thomas D Brothers; Keith Hansen; Alexander Caudarella; Wiplove Lamba; Tim Guimond
Journal:  Am J Addict       Date:  2019-10-18

7.  Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.

Authors:  Denis Antoine; Andrew S Huhn; Eric C Strain; Gavin Turner; Jasmyne Jardot; Alexis S Hammond; Kelly E Dunn
Journal:  Am J Addict       Date:  2020-06-23

8.  Low-dose Buprenorphine Initiation in Hospitalized Adults With Opioid Use Disorder: A Retrospective Cohort Analysis.

Authors:  Dana Button; Jennifer Hartley; Jonathan Robbins; Ximena A Levander; Natashia J Smith; Honora Englander
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

9. 

Authors:  Radhika Marwah; Caitlin Coons; Jacqueline Myers; Zack Dumont
Journal:  Can Fam Physician       Date:  2020-12       Impact factor: 3.275

10.  Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach.

Authors:  Mackenzie Duncan Gregory Caulfield; Rupinder Brar; Christy Sutherland; Seonaid Nolan
Journal:  BMJ Case Rep       Date:  2020-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.